DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR IXABEPILONE
Clinical Trials for Ixabepilone
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00004927 | BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy | Completed | Memorial Sloan Kettering Cancer Center | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have advanced solid tumors that have not responded to previous therapy. |
| NCT00004927 | BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy | Completed | National Cancer Institute (NCI) | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have advanced solid tumors that have not responded to previous therapy. |
| NCT00004927 | BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy | Completed | Bristol-Myers Squibb | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have advanced solid tumors that have not responded to previous therapy. |
| NCT00005807 | BMS-247550 in Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer | Completed | National Cancer Institute (NCI) | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have metastatic, recurrent, or locally advanced, ovarian cancer, breast cancer, or metastatic or unresectable solid tumors. |
| NCT00005807 | BMS-247550 in Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer | Completed | Albert Einstein College of Medicine of Yeshiva University | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have metastatic, recurrent, or locally advanced, ovarian cancer, breast cancer, or metastatic or unresectable solid tumors. |
| NCT00006221 | BMS-247550 in Treating Patients With Advanced Cancers | Completed | National Cancer Institute (NCI) | Phase 1 | Phase I trial to study the effectiveness of BMS-247550 in treating patients who have malignant solid tumors or lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. |
| NCT00016393 | BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | Completed | National Cancer Institute (NCI) | Phase 2 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have prostate cancer that has not responded to hormone therapy. |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Ixabepilone
Condition Name
Condition MeSH
Clinical Trial Locations for Ixabepilone
Trials by Country
Clinical Trial Progress for Ixabepilone
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Ixabepilone
Sponsor Name
